Research location
Yongzhou
Hunan, China
Advertisement
Research activity in Yongzhou
Hunan, ChinaCureCurrent currently publishes aggregate city-level research activity for this location: 19 trials and 19 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Yongzhou
19 linked trials · page 1 of 1Precision Navigation to Improve Community Cancer Screening ParticipationNCT07676383 · 2026-08-04 · 1 site observation
RECRUITING
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseaseNCT07464587 · 2026-04-14 · 1 site observation
RECRUITING
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerNCT07047365 · 2025-07-25 · 1 site observation
RECRUITING
A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT07292714 · 2025-07-15 · 1 site observation
RECRUITING
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerNCT06889688 · 2025-02-21 · 1 site observation
RECRUITING
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerNCT07673029 · 2025-01-10 · 1 site observation
RECRUITING
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.NCT06064812 · 2023-09-12 · 1 site observation
RECRUITING
Evaluation of Chiglitazar Sodium With Lifestyle Intervention for Reversing PrediabetesNCT07558525 · 2026-04-18 · 1 site observation
NOT_YET_RECRUITING
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseaseNCT07147946 · 2025-09-01 · 1 site observation
NOT_YET_RECRUITING
Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerNCT06851442 · 2025-05-16 · 1 site observation
TERMINATED
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)NCT06680921 · 2024-11-14 · 1 site observation
ACTIVE_NOT_RECRUITING
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBCNCT06419621 · 2024-06-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of NatureU Burn on Satiety in Healthy AdultsNCT07597382 · 2024-04-22 · 1 site observation
COMPLETED
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)NCT06018337 · 2024-01-18 · 1 site observation
ACTIVE_NOT_RECRUITING
FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerNCT05755048 · 2023-03-28 · 1 site observation
UNKNOWN
Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast CancerNCT05555706 · 2022-12-06 · 1 site observation
COMPLETED
Bleeding Intracerebral Hemorrhage With Early Invasive Intracranial Pressure Monitoring TrialNCT05593380 · 2022-11-15 · 1 site observation
COMPLETED
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast CancerNCT05433480 · 2022-05-25 · 1 site observation
UNKNOWN
A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) PatientsNCT04237805 · 2016-11-14 · 1 site observation
UNKNOWN
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.